Precision Revisited: Targeting Microcephaly Kinases in Brain Tumors by Pallavicini, G. et al.
 International Journal of 
Molecular Sciences
Review
Precision Revisited: Targeting Microcephaly Kinases
in Brain Tumors
Gianmarco Pallavicini 1,2,3, Gaia E. Berto 1,2 and Ferdinando Di Cunto 1,2,4,*
1 Neuroscience Institute Cavalieri Ottolenghi, 10126 Turin, Italy; gianmarco.pallavicini@unito.it (G.P.);
gaia.berto@unito.it (G.E.B.)
2 Department of Neurosciences, University of Turin, 10126 Turin, Italy
3 Department of Molecular Biotechnology and Health Sciences, University of Turin, 10126 Turin, Italy
4 Neuroscience Institute of Turin (NIT), 10126 Turin, Italy
* Correspondence: ferdinando.dicunto@unito.it
Received: 26 March 2019; Accepted: 26 April 2019; Published: 28 April 2019


Abstract: Glioblastoma multiforme and medulloblastoma are the most frequent high-grade brain
tumors in adults and children, respectively. Standard therapies for these cancers are mainly based
on surgical resection, radiotherapy, and chemotherapy. However, intrinsic or acquired resistance to
treatment occurs almost invariably in the first case, and side effects are unacceptable in the second.
Therefore, the development of new, effective drugs is a very important unmet medical need. A critical
requirement for developing such agents is to identify druggable targets required for the proliferation
or survival of tumor cells, but not of other cell types. Under this perspective, genes mutated in
congenital microcephaly represent interesting candidates. Congenital microcephaly comprises a
heterogeneous group of disorders in which brain volume is reduced, in the absence or presence of
variable syndromic features. Genetic studies have clarified that most microcephaly genes encode
ubiquitous proteins involved in mitosis and in maintenance of genomic stability, but the effects of
their inactivation are particularly strong in neural progenitors. It is therefore conceivable that the
inhibition of the function of these genes may specifically affect the proliferation and survival of brain
tumor cells. Microcephaly genes encode for a few kinases, including CITK, PLK4, AKT3, DYRK1A,
and TRIO. In this review, we summarize the evidence indicating that the inhibition of these molecules
could exert beneficial effects on different aspects of brain cancer treatment.
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1. Background
1.1. The Hurdles of High-Grade Brain Tumor Precision Medicine
High-grade brain tumors (HGBTs) are very aggressive cancers that represent an important unmet
medical challenge. Medulloblastoma (MB) is the most common pediatric HGBT, and it also occurs
in adults, although less frequently. Based on microarray and genomic sequencing technologies,
MB has been classified into four biological subgroups (WNT, SHH, group 3, and group 4) [1,2]. MB is
currently treated with surgery, followed by irradiation of the entire neuraxis and high-dose multiagent
chemotherapy. The long-term survival rate can be as high as 90% in the rare WNT subgroup, but it is
usually around 50% in most of the other cases, with the worst prognosis in group 3 and 4 patients [3,4].
Thus, many patients still die despite treatment, and those who survive suffer from neurological,
cognitive, and endocrine disorders caused by the aggressive therapy [3,4].
In adulthood, the most frequent HGBTs are gliomas. Among them, glioblastoma multiforme
(GBM) is one of the deadliest human cancers. According to the WHO, GBM accounts for approximately
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12%–15% of all brain tumors, and 60%–70% of astrocytic tumors [5]. The standard therapy for GBM is
mainly based on surgical resection in combination with radiotherapy and chemotherapy with alkylating
agents, such as temozolomide (TMZ). Gene expression profiling has allowed for the classification
of GBM into four distinct subtypes (i.e., proneural, neural, classical, and mesenchymal) associated
with distinct genomic abnormalities and different responses to aggressive therapy [6]. Nevertheless,
the longest median survival obtained in GBM patients treated with combined therapy has been
14 months [7].
For these reasons, more effective and specific therapies are urgently needed for HGBTs.
A common assumption is that the most straightforward strategy to develop new anticancer
therapies is to directly target driver mutations, as well as molecular pathways connected to them.
A paradigm for this approach is the dramatic improvement in therapy of chronic myeloid leukemia,
determined by the introduction of ABL1 tyrosine kinase inhibitors [8], but the extension of this approach
to other tumors faces many issues.
In the case of MB, targeted therapy has been developed for the SHH subtype. This subgroup,
which represents approximately 30% of MB patients in children and more than 50% in adults, could take
advantage of Vismodegib and other smoothened (SMO) inhibitors [9,10]. However, only a subgroup
of these patients respond to treatment and, even in these cases, resistance rapidly develops [9,11].
As with many other pediatric cancers, MB is characterized by a low mutation burden [12], leading
to a paucity of recurrent alterations. In addition, the recurrent mutations found in groups 3 and
4 involve NMYC amplification, CTNNB1, PRDM6, and TERT variants, which are difficult to target
pharmacologically [13].
The current state of precision approaches is not better for GBM. In these tumors, many recurrent
mutations are routinely identified, such as those involving growth factor receptors, MAPK, and
PI3K/mTOR signaling pathways or inhibitors of cell cycle progression [6,14]. However, these variants
have not been associated with clear prognostic and predictive results, challenging the assumption that
they are strong cancer drivers. Even more disappointingly, no therapy against these targets has shown
significant efficacy in clinical trials, probably as a consequence of cancer cell plasticity, redundancy
among alterations, and intratumor genomic heterogeneity [15].
The application of immune checkpoint blockade strategies in HGBTs does not appear to provide
much better perspectives. MB is not expected to be very responsive to these treatments, because of the
low mutation burden and scarce inflammatory infiltrate [13]. On the other hand, despite encouraging
preclinical results, clinical trials with PD1-PDL1 inhibitors have not shown a significant benefit in GBM,
probably due to the strong immunosuppressive environment of these tumors [16].
A relatively unexplored alternative is to target molecules and mechanisms that, despite not
being mutated, are nevertheless required for tumor growth, progression, and invasiveness [17].
Screening-based strategies have been proposed to identify cancer vulnerabilities in specific
patients [18], but the time required for deploying such strategies is a strong barrier to their efficient
practical implementation.
1.2. Congenital Microcephaly: A Tissue-Specific Phenotype of Ubiquitously Expressed Genes
A major problem for precision medicine is to understand whether and how the effects of
tumor-driving mutations, as well as tumor responses to therapeutic agents, are rooted in the biology
of cells that have undergone malignant transformation [19]. Specific epigenomic landscapes and
local proteome composition may render a particular tissue or cell type permissive to particular
oncogenic mutations, but may also result in tissue-specific vulnerabilities that could be exploited
therapeutically [19].
On this ground, genes mutated in congenital microcephaly (CM) syndromes have been proposed
as attractive targets for HGBT-directed drug development [20–22]. HGBTs originate from different
types of neural progenitors. Although it is still debated from which precursors the different cancers
originate, it is established that MB and GBM tumor cells share many molecular features with cerebellar
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granule progenitors and cortical radial glia cells, respectively [23,24]. The inactivation of genes
associated with congenital microcephaly leads to specific alterations of proliferation and survival of
such cells.
CM is a heterogeneous group of disorders characterized by reduced head circumference at birth,
to at least 3 standard deviations below the mean [25,26]. CM can be the result of nongenetic conditions,
such as viral infections and toxic exposure, or it can be generated by rare genetic disorders [25].
Primary hereditary microcephaly (MCPH) is the simplest form of genetic CM, in which brain size
reduction is accompanied by grossly normal brain architecture and mild to moderate intellectual
disability [25,27]. The association of severe microcephaly and proportionate body growth reduction is
instead characteristic of Seckel syndrome (SCKS). Pure MCPH and SCKS are rare conditions, since
genetic CM is more often associated with syndromic features and comorbidities [25,26,28]. In the
Online Mendelian Inheritance in Man (OMIM) database (https://www.omim.org), approximately
450 loci are linked to mendelian phenotypes in which microcephaly is a strong hallmark.
A striking common feature of these genes is that, during development, they are selectively
required for proliferation and genomic stability of neural progenitors, despite being expressed in
all proliferating cell types [29]. The biological basis of this specificity is only partially understood.
In many cases, CM proteins are associated with centrosomes, and their loss leads to cell cycle and
mitosis delay, mitotic failure, and randomization of spindle orientation [30]. These alterations may tilt
the balance between symmetric and asymmetric divisions of neural stem cells, decreasing the pool of
proliferating neural progenitors and/or increasing the frequency of premature commitment or terminal
differentiation [30]. However, it has also been shown that the loss of many MCPH proteins leads to the
accumulation of DNA damage and apoptosis [31–33]. Moreover, there is evidence that nongenetic
insults associated with microcephaly could impinge on the same tissue-specific vulnerabilities [34].
Accordingly, oncolytic activity by the ZIKA virus has been proposed as a therapeutic strategy for
GBM [35–37].
Regardless of the precise mechanisms, the inactivation of CM genes may specifically reduce the
expansion of HGBT cells. As in normal neural progenitors, CM gene inhibition could impair cancer
cell cycle progression, promote differentiation, and induce apoptosis, with marginal effects on normal
cell types. Moreover, the inactivation of CM genes may sensitize HGBT cells to radiotherapy and
chemotherapy [20].
Proof of concept about the suitability of MCPH genes as possible therapeutic targets has already
been reported for ASPM, the gene mutated at the highest frequency in MCPH patients, as well as
for KIF14 and CDK6. ASPM loss has been found to arrest the proliferation of glioma stem cells [38],
to radiosensitize GBM cell lines [39], and to reduce tumor growth in MB mouse models [32] by
increasing DNA double strand break (DSB) accumulation [32,39]. Similar results have been obtained by
inducing KIF14 depletion [40,41]. Finally, CDK4/6 inhibitors have displayed significant antineoplastic
activity in pro-neural GBM cells in xenograft assays [42], and new inhibitors of these kinases capable of
crossing the blood–brain barrier are actively being developed [43]. However, very little is known about
the potential of other CM genes, as well as about the mechanisms that could influence their specificity.
CM-associated genes encode for some protein kinases. Considering their druggability, these
proteins could represent a very interesting group of targets for HGBTs. Among them, CDK6 and
CITK are involved in MCPH. On the other hand, mutations in ATR, PLK4, AKT3, DYRK1A, and TRIO
have been associated with genetic disorders in which brain development is less specifically affected,
leading to syndromic forms of CM. The potential of CDK6 and ATR as targets for MB and GBM has
been deeply addressed in a recent review [22]. We therefore concentrate our survey on the remaining
kinases (Figure 1).
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Figure 1. Convergent molecular pathways of microcephaly kinases CITK, PLK4, DYRK1A, AKT3, and 
TRIO. Their signaling cascades impinge, throughout the indicated common genes, on cytoskeletal 
dynamics and DNA damage responses or directly on proliferation and apoptosis. The indicated 
phosphorylation events (yellow P circles) have been experimentally proven. 
1.3. Citron Kinase (CITK) 
CITK is a conserved AGC-type serine/threonine kinase. In mammals, it is the largest product of 
the CIT gene, with a molecular mass of 230 kD [44,45]. It displays a modular organization very similar 
to other members of the myotonic dystrophy kinase subfamily, comprising Rho-kinases (ROCKs) 
and CDC42BPA/CDC42BPB kinases (also known as MRCKs) [46]. These proteins share an amino-
terminal kinase domain, followed by an extended coiled-coil region, a type 2 zinc finger, and a 
Pleckstrin homology domain (PH). CITK and MRCKs are characterized by a Citron-Nik1 homology 
(CNH) domain [45].  
CITK is ubiquitously expressed in proliferating cells, with the highest levels in the G2/M phase 
of the cell cycle [47]. It is enriched at spindle poles before anaphase [48] and concentrates at cleavage 
furrows and midbody during cytokinesis [45]. The best studied function of CITK is to regulate 
midbody maturation and abscission at the end of cytokinesis [45,48–51], in concert with anillin 
(ANLN) [48], microtubule-binding proteins MKLP1, PRC2, and KIF14 (encoded by microcephaly 
gene MCPH20) [49], as well as chromosomal passenger complex (CPC) [52] and Casein kinase 2 [53]. 
CITK is also required for localization of F-actin at the abscission sites for the final cut of the midbody 
[51].  
The only validated substrate of CITK is CPC component INCENP, whose phosphorylation by 
CITK regulates midbody organization by mediating a positive feedback loop between local CITK 
recruitment and AURKB activation [52]. CITK also regulates mitotic spindle orientation by 
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with ASPM (encoded by the microcephaly gene MCPH5) [48]. Finally, CITK prevents the accumulation
of DNA double strand breaks independently of its role in cytokinesis and affects recruitment of RAD51
at DNA-damage foci [31].
Despite ubiquitous expression, CITK is functionally required in vivo only in a few cell types,
including neural progenitors [54,55] and male germ cells [56]. Consequently, CITK loss leads to severe
microcephaly in rodents [54,55] and humans [57–60]. Cells in the affected tissues display cytokinesis
failure, apoptosis, and the accumulation of DNA damage [31,54,57,58]. The syndrome associated with
CITK mutations is a particularly severe form of CM, known as MCPH17. Head circumference can be
as low as 8 standard deviations below the mean, with moderate or severe intellectual disability. Many
patients show a short stature and spasticity, and a few cases also display renal agenesis. Notably, in
approximately half of MCPH17 patients, homozygous missense mutations in the kinase domain have
been found, resulting in a loss of catalytic activity [58]. Together with the other data, the latter evidence
underscores that CITK activity is at the center of a complex interaction network essential for normal
proliferation and survival of neural progenitors, comprising many other CM-associated proteins.
Concerning its possible role as a cancer drug target, CITK has long been a “neglected” protein [61],
probably due to its highly specific developmental role.
As with most microcephaly proteins, CITK is expressed at high levels in tumors [62–64], but
this could likely be a reflection of cell-cycle regulated expression. Despite its strong tissue-specific
requirement in normal cells, CITK knockdown negatively impacts the proliferation of tumor cell lines
of different origins, in which it consistently induces cytokinesis failure, resulting in the accumulation
of multinucleated cells [65,66].
The possible usefulness of CITK as a target for CNS tumor treatment has recently been explored
in MB models [67]. CITK depletion by RNAi impairs in vitro expansion of MB cell lines and limits the
growth of xenograft tumors. Moreover, temporally controlled deletion of CITK in tumors arising in
the transgenic SmoA1 MB model reduces tumor growth and increases survival. In all models, CITK
loss has been accompanied by cytokinesis failure, as well as by DNA damage and the induction of
cell senescence. Interestingly, similar effects were obtained both in P53-proficient and P53-deficient
cells [67]. At the moment, no data are available on the possible requirement for CITK in GBM cells,
and no specific inhibitors of CITK have been reported.
1.4. Polo-Like Kinase 4 (PLK4)
PLK4 is one of the members of the Polo-like proteins, a kinase subfamily that plays a pivotal role
in cell cycle progression and cytokinesis [68]. It is characterized by an N-terminal kinase domain,
closely related to other PLKs. However, it shows a divergent carboxy-terminal domain, containing a
single polo-box domain (PBD) instead of two tandem PBDs [68]. Polo boxes of PLK4 are involved
in protein–protein interactions and control kinase activation, protein localization, and substrate
specificity [69]. The PDB functions as a phosphoserine/threonine-binding module that has the highest
affinity for Ser-[pSer/pThr]-[Pro/X], suggesting that PLK4 binds to docking sites primed by CDKs,
MAP kinases, and other mitotic kinases [70].
In vivo expression of PLK4 is correlated with proliferation, and is very high in embryonic tissues
and adult testes, moderate in the spleen and thymus, and not detectable in the brain, lungs, kidneys,
breasts, heart, ovaries, and liver [71]. Expression peaks during the S, G2, and M phases of the cell cycle,
while kinase activity is induced in the S phase and doubles from S to G2 [72].
PLK4 is localized in the nucleolus during G2, becomes enriched at centrosomes in the M phase, and
concentrates at the midbody in cytokinesis [73]. In the centrosome, PLK4 is specifically concentrated at
the proximal ends of the centriole outer wall and has also been observed close to the distal appendages
of the mother centriole [74].
Consistent with its localization, PLK4 plays a fundamental role in centriole duplication [75]. PLK4
knockdown leads to centriole loss [75], while PLK4 overexpression increases centrioles’ number [74],
producing abnormal spindle and mitotic abnormalities in both cases [76,77]. In mammals, centriole
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biogenesis is initiated by CEP192 and CEP152 (MCPH9), which recruit PLK4 to the proximal end
of the mother centriole [78,79]. An interaction between PLK4 and STIL (MCPH7) results in STIL
phosphorylation [80] and subsequent recruitment of SASS6 (MCPH14), which initiates nine-fold
symmetric cartwheel nucleation and γ-tubulin assembly [81]. PLK4 also phosphorylates CHK2, a key
transducer of ATM and ATR in the DNA damage response [82]. Therefore, PLK4 physically and
functionally interacts with the products of many CM genes.
Homozygous deletion of PLK4 in mice is embryonically lethal at the postgastrulation stage, with
a marked increase in mitotic and apoptotic cells [73]. PLK4 +/− mouse embryonic fibroblasts have
demonstrated a high rate of primary cytokinesis failure, associated with aberrant acto-myosin ring
formation, reduced RHOA activation, and failure to localize the RHOA guanine nucleotide exchange
factor ECT2 to the midbody [83].
Although these data suggest a direct involvement of PLK4 in cytokinesis, further studies have
excluded this possibility, indicating that cytokinesis failure from decreased PLK4 function is only an
indirect consequence of the spindle abnormalities caused by centrioles [84].
Despite PLK4′s house-keeping functions in mitosis, the identification of PLK4 mutations in
microcephaly patients has provided evidence that neural progenitors are particularly sensitive to its
levels. Homozygous truncating mutations in PLK4 have been identified in seven affected members of a
consanguineous family with autosomal recessive microcephaly, short statures, and chorioretinopathy,
as well as in another two unrelated families [85]. A similar phenotype resulted from mutations in
the PLK4 substrate TUBGCP6 [85]. Patient fibroblasts showed reduced centriole numbers, abnormal
spindle formation, and decreased numbers of ciliated cells, correlating with the absence of basal bodies.
However, patients did not show a ciliopathy phenotype [85]. In addition, patients’ cells showed
genomic instability and altered DNA damage response [86].
There is abundant evidence that the alteration of PLK4 levels and activity may play a general
driver role in cancer and that PLK4 expression is deregulated in many cancer types [69]. Notably,
PLK4 acts as a tumor suppressor in haplo-insufficiency conditions by causing mitotic infidelity [87]
and as an oncogene in overexpression conditions [88]. Centrosome amplification associated with PLK4
overexpression and its correlation with poor prognosis has been reported in many cancer types [69].
Moreover, the promotion of actin nucleation and invasiveness through phosphorylation of the Arp2/3
complex may contribute to PLK4 pro-metastatic potential [89].
These findings have led to rising interest in PLK4 as a promising and feasible target for cancer
therapy and to the consequent development of PLK4 inhibitors. The first of such compounds was
CFI-400945, which is capable of inducing mitotic defects and cell death in epithelial tumor cells [90].
In particular, CFI-400945 was reported to inhibit the growth of patient-derived pancreatic xenografts [91]
and to induce polyploidy and cell death in lung cancer cells [92]. However, controversy exists about the
specificity of this compound, because it leads to centrosome amplification, rather than the centrosome
loss that would be expected from PLK4 inhibition [93]. This phenotype could be explained in part by
the fact that CFI-400945 is also able to inhibit AURKB, leading to cytokinesis inhibition, in part by a
feedback loop derived from partial PLK4 inhibition, preventing the degradation of autophosphorylated
protein [94]. The latter mechanism could promote a paradoxical increase in PLK4 levels, with actual
PLK4-dependent centrosome amplification [93].
A more specific compound is Centrinone, whose administration leads to total but reversible
centrosome loss [95]. This compound has allowed for demonstrating that centrosomes are essential
to the proliferation of normal cells, which undergo a permanent P53-dependent growth arrest upon
Centrinone treatment [96]. In contrast, cancer cells continue to proliferate after centrosome loss,
suggesting that centrosome depletion must be combined with other perturbations to selectively target
them [93].
PLK4 is upregulated in embryonal CNS cancers, such as brain rhabdoid tumors [97],
medulloblastoma [97,98], and neuroblastoma [99]. Rhabdoid cells within which PLK4 was targeted
by CRISPR/CAS9 demonstrated significantly decreased proliferation, viability, and survival [100].
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The PLK4 inhibitor CFI-400945 showed cytotoxic effects on rhabdoid tumor cell lines, while sparing
non-neoplastic human fibroblasts and developing zebrafish larvae [100].
PLK4 inhibition has induced apoptosis, senescence, and polyploidy in MB cells, thereby increasing
the susceptibility of cancer cells to DNA-damaging agents [97]. In malignant gliomas, elevated PLK4
levels were associated with poor prognosis and enhanced radio-resistance, while PLK4 knockdown
significantly increased the radio-sensitivity of GBM cells [101]. The sensitivity of GBM cells to TMZ was
also decreased by ectopic expression of PLK4 and was enhanced by PLK4 depletion and CFI-400945
treatment [102]. No reports are available on the effects of Centrinone in HGBT cells.
1.5. AKT Serine/Threonine Kinase 3 (AKT3)
AKT3 is one of three closely related serine/threonine-protein kinases, also called PKB, belonging
to the family of AGC ser/thr protein kinases. These proteins share a conserved structure that includes
three functional domains: an N-terminal PH domain, a central kinase domain, and a C-terminal
regulatory domain containing the hydrophobic motif phosphorylation site [FxxF(S/T)Y] [103,104].
AKT1 and AKT2 play partially redundant roles in many processes of normal and cancer cells, including
metabolism, proliferation, cell survival, growth, and angiogenesis [103,105,106].
AKT3 mRNA is expressed in many tissues, with the highest levels in the brain, testes, lungs,
heart, kidneys, mammary glands, and fat [107]. It is activated by insulin through a PI3K-dependent
mechanism requiring the PH domain and thr-305 phosphorylation [107,108]. AKT3 is the most
represented AKT paralog in the brain during neurogenesis, and levels of phosphorylated pan-AKT are
abundant in cortical progenitor cells during cortical development [109].
Akt3 -/- mice show a selective 20% decrease in brain volume and hypoplasia of the corpus callosum,
resulting from the reduction of both cell size and cell numbers [110,111]. This phenotype differs from
Akt1 -/- mice, in which brain size is reduced in the context of global body size decrease [110].
In consideration of the mouse knockout phenotype and its chromosomal localization (1q23-24),
AKT3 is considered the strongest candidate gene for 1q22-24 deletion syndrome, characterized by
microcephaly and corpus callosum agenesis [112]. Identification of a balanced reciprocal t(1;13)(q44;q32)
translocation in a patient with a similar phenotype, with a breakpoint close to the AKT3 promoter, further
supported this association [112]. Conversely, activating germline and somatic AKT3 mutations have
been identified as a rare cause of megalencephaly and hemimegalencephaly, respectively [109,113,114].
The brain-specific role of AKT3 is at least partially explained by its expression pattern, since
this kinase shares the same activation mechanisms and most substrates with its paralogs [115]. Thus,
microcephaly could be explained by pro-proliferative and antiapoptotic effects on neural progenitors.
However, it is possible that subtler mechanisms exist [115].
The AKT pathway is hyperactive in a large fraction of human cancers, including brain tumors [116].
Selective activation of AKT3 through overexpression or copy number increase is a recurrent event in
nonfamilial melanomas [117]. AKT3 amplification has also been found in GBM [118] and MB [119].
AKT3 is required in transformed astrocytes and human glioma cells for anchorage-independent growth,
and its loss has inhibited transformed cell invasion [120,121]. AKT3-expressing human GBM cells have
shown enhanced activation of DNA repair proteins, leading to increased DNA repair and subsequent
resistance to radiation and TMZ [122]. Accordingly, AKT3 knockdown had synergistic effects with
TMZ and BCNU [123]. The development of therapeutic strategies based on selective and nonselective
inhibitors of AKT3 and other AKTs represents an area of intensive investigation [116].
1.6. Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (DYRK1A)
DYRK1A is a dual-specificity kinase regulated by tyrosine phosphorylation, belonging to the
CMGC protein kinase family [124,125]. Human DYRK1A is a multidomain protein containing a
highly conserved kinase domain preceded by a DH domain, which is characteristic of the DYRK
kinase subfamily. In addition, it also contains two different nuclear localization signals, a PEST region,
a histidine-rich region, and an extreme C-terminal region rich in serine and threonine. DYRK1A is
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capable of intermolecular activating autophosphorylation on tyrosine residues and phosphorylates its
substrates on serine/threonine [124,126].
DYRK proteins are homologous to the Drosophila minibrain gene, and DYRK1A is widely known
for its role in Down syndrome (DS). It is one of the more actively studied genes of the Down critical
region, a relatively small part of human Chromosome 21 that plays a paramount role in DS-associated
intellectual disability [125,127].
DYRK1A is expressed in most tissues, but during embryogenesis it is most abundant in the
brain, spinal cord, and retina [128]. Homozygous deletion of Dyrk1a in mice is embryonically lethal,
leading to general growth delay and death during midgestation. Heterozygous mice have shown
decreased neonatal viability, reduced body size from birth to adulthood, and region-specific brain size
decrease [129].
Accordingly, heterozygous DYRK1A deletion [130], as well as truncating and missense
variants [131], have been found in patients showing microcephaly, intellectual disability, and autism
spectrum symptoms. Both increased and decreased DYRK1A dosages have profound effects on
neural progenitor biology. DYRK1A loss of function severely affects neural lineage specification [132],
while the 1.5–2-fold increased expression that characterizes DS slows cell cycle progression, reduces
progenitor pools, and impairs neuroblast differentiation in the developing neocortex [133].
Through the identification of substrates and interactors, DYRK1A has been involved in a broad
range of cellular processes, including cell cycle regulation, cellular signaling, gene expression, chromatin
modulation, alternative splicing, and membrane trafficking [134]. In particular, it has been shown
to promote cell survival through different mechanisms, including inhibitory phosphorylation of
Caspase 9 [135,136], priming phosphorylation of NFAT in the GSK3 pathway [137,138], and SIRT1
phosphorylation in response to genotoxic stress, in turn inhibiting TP53 activity and apoptosis [139].
Moreover, it may affect microtubule dynamics by phosphorylating β-Tubulin [140] and Tau [141].
Both tumor-suppressive and pro-oncogenic roles have been suggested for DYRK1A [134], especially
in relation to brain tumors. In gliomas, it has been reported that DYRK1A may destabilize HIF2-alpha
in hypoxic conditions by phosphorylating thr27 of ID2, leading to reduced self-renewal of glioma stem
cells, the inhibition of tumor growth, and more favorable outcomes for patients with glioblastoma [142].
On the other hand, DYRK1A inhibition promotes EGFR degradation in primary GBM cells, thus
compromising their survival and producing a profound decrease in tumor burden [143]. Accordingly,
some novel, potent inhibitors (IC50 ≤50 nM) are capable of significantly decreasing viability, clonogenic
survival, migration, and invasion of glioblastoma cells [144]. DYRK1A has also been shown to interfere
with Shh/Gli signaling in MB [145].
1.7. Trio Rho Guanine Nucleotide Exchange Factor (TRIO)
The TRIO name derives from its sequence containing three main functional domains: two guanine
nucleotide exchange domains for Rho-family small GTPases (GEFD1 and GEFD2), composed of a Dbl
homology region followed by a PH domain, as well as one C-terminal ser/thr kinase domain [146].
In addition, TRIO comprises other modular units belonging to different structural classes [147].
TRIO was originally identified as an interactor of receptor tyrosine phosphatase LAR and is ubiquitously
expressed with many different isoforms [146].
The principal functional regions of TRIO are the two GEFDs, which are capable of inducing actin
remodeling through Rho GTPases. In particular, GEFD1 activates both RAC1 and RHOG, while GEFD2
acts specifically on RHOA [146,148]. The kinase domain is constitutively tyrosine-phosphorylated
and interacts with LAR and with FAK. Increased tyrosine phosphorylation after FAK cotransfection
increases TRIO association with the cytoskeleton [149].
A complete loss of function of TRIO is embryonically lethal in mice between E15.5 and birth, with a
few escapers surviving for no more than one month [150]. Trio -/- mice display abnormal myotube
fusion and aberrant organization in several brain regions, including in hippocampal formation and in
the olfactory bulb [150].
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Exome sequencing has revealed that TRIO is a haplo-insufficient gene, since heterozygous
germline or de novo mutations have been found in several patients, characterized by delays in the
acquisition of motor and language skills, mild to borderline intellectual disability, neurobehavioral
problems, and microcephaly [151,152]. TRIO mediates axon outgrowth and guidance in response to
extracellular cues transduced by different receptors. For instance, it may act downstream of the NGF
receptor by activating RHOG through GEFD1 [153]. Moreover, it promotes signal transduction through
axon-guidance receptor DCC, by favoring its membrane insertion and by becoming phosphorylated by
tyrosine kinase FYN when DCC is bound by its ligand netrin-1. FYN-mediated tyrosine phosphorylation
enhances the activity of GEFD1 toward RAC1, thereby promoting actin dynamics at the growth
cone [154].
A very important function of TRIO for its involvement in cancer is to control cell adhesion and
migration, especially downstream of Cadherin proteins [147]. For instance, both GEFD1 and GEFD2
are essential to mediate the collective migration of neural crest cells downstream of Cadherin-11.
Upregulation of TRIO expression, often associated with poor patient survival, is found in different
tumor types, including urinary bladder, breast, lung soft tissue sarcoma, and glioblastoma [147].
TRIO mediates glioma cell migration and invasion produced by stimulation of the TWEAK-Fn14
signaling axis by inducing RAC1 activation [155]. Accordingly, TRIO-directed siRNA oligonucleotides
suppress glioblastoma cell migration and invasion and also reduce the rate of cell proliferation [156].
Compared to other kinases, TRIO is a more challenging target for pharmacological development,
because the kinase domain is not crucial for function. Nevertheless, peptide aptamer-based [157] and
small-molecule inhibitors [158], both interfering with the binding of GEF domains to cognate GTPases,
are being developed.
2. Remarks and Conclusions
Sufficient evidence exists to support the notion that protein kinases associated with CM are
promising targets for HGBT treatment. The results obtained through the inactivation or depletion of
these proteins consistently have shown that, by interfering with microcephaly-related mechanisms,
it is possible to decrease tumor cell clonal expansion, increase their sensitivity to chemotherapy
and radiotherapy, and decrease their invasiveness. In many cases, experiments performed with the
available inhibitors in vitro or with heterotopic xenograft models have provided proof of concept about
their possible usefulness in therapy. However, many problems remain to be solved. In most of the
studied cases, important pharmacological issues exist, especially concerning inhibitor development
and/or delivery through the blood–brain barrier. Most inhibitors have not been tested yet in transgenic
or orthotopic models, which more closely resemble the in vivo human condition. Since it is difficult to
imagine that inhibitors of CM genes could be used as a monotherapy, a big effort is needed to address
the effects of combining them with radiotherapy and chemotherapy, both in xenograft and orthotopic
models. Moreover, it would be very interesting to study the effects of simultaneously inhibiting
CM genes impinging on similar or different mechanisms. On these bases, although the inhibition of
ubiquitous kinases may appear to be an old-fashioned approach, we are convinced that the underlying
biological complexity may still offer a field with great potential.
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